Literature DB >> 26830289

Inhibiting Matrix Metalloproteinase 3 Ameliorates Neuronal Loss in the Ganglion Cell Layer of Rats in Retinal Ischemia/Reperfusion.

Tu Hu1, Qiuting You2, Dan Chen1, Jianbin Tong3, Lei Shang1, Jia Luo1, Yi Qiu2, Huimin Yu4, Leping Zeng5, Jufang Huang6.   

Abstract

It has been demonstrated that matrix metalloproteinase 3 (MMP3) is integrally involved in the neuronal degeneration of the central nervous system by promoting glial activation, neuronal apoptosis and damage to the brain-blood barrier. However, whether MMP3 also contributes to the neuronal degeneration induced by retinal ischemia/reperfusion is still uncertain. In the present study, we detected the cellular localization of MMP3 in adult rat retinae and explored the relationship of its expression with neuronal loss in the ganglion cell layer (GCL) in retinal ischemia/reperfusion. We found that MMP3 was widely expressed in many cells throughout the layers of the rat retinae, including Vertebrate neuron-specific nuclear protein (NeuN)-, parvalbumin-, calbindin-, protein kinase C-α-, glial fibrillary acidic protein-, glutamine synthetase- and CD11b-positive cells. Furthermore, all rats were treated with high intraocular pressure (HIOP) for 1 h (h) and sacrificed at 6 h, 1 day (d), 3 d, and 7 d after HIOP. Compared to the normal control, the expression of both proenzyme MMP3 and active MMP3 were significantly up-regulated after HIOP treatment without alteration of the laminar distribution pattern. Moreover, inhibiting MMP3 ameliorated the loss of NeuN-positive cells in the GCL following HIOP. In summary, our data demonstrates that MMP3 is expressed in multiple types of neurons and glial cells in normal rat retinae. Simultaneously, the up-regulation of its expression and activity are closely involved in neuronal loss in the GCL in retinal ischemia/reperfusion.

Entities:  

Keywords:  High intraocular pressure; Matrix metalloproteinase 3; N-Isobutyl-N-(4-methoxyphenylsulfonyl)glycyl-hydroxamic acid; Retinal ischemia/reperfusion

Mesh:

Substances:

Year:  2016        PMID: 26830289     DOI: 10.1007/s11064-015-1800-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  41 in total

1.  Age of rats seriously affects the degree of retinal damage induced by acute high intraocular pressure.

Authors:  Chang Tan; Tu Hu; Ming-chao Peng; Shu-li Liu; Jian-bin Tong; Wen Ouyang; Yuan Le
Journal:  Curr Eye Res       Date:  2014-08-25       Impact factor: 2.424

2.  Matrix-degrading enzymes tissue plasminogen activator and matrix metalloprotease-3 in the hypothalamo-neurohypophysial system.

Authors:  Seiji Miyata; Yoshihiro Nakatani; Noriko Hayashi; Toshihiro Nakashima
Journal:  Brain Res       Date:  2005-09-16       Impact factor: 3.252

3.  Caspase-8 promotes NLRP1/NLRP3 inflammasome activation and IL-1β production in acute glaucoma.

Authors:  Wei Chi; Fei Li; Hongrui Chen; Yandong Wang; Yingting Zhu; Xuejiao Yang; Jie Zhu; Frances Wu; Hong Ouyang; Jian Ge; Robert N Weinreb; Kang Zhang; Yehong Zhuo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

4.  Matrix metalloproteinase-3 is increased and participates in neuronal apoptotic signaling downstream of caspase-12 during endoplasmic reticulum stress.

Authors:  Eun-Mee Kim; Eun-Jung Shin; Ji Hyun Choi; Hyo Jin Son; Il-Seon Park; Tong H Joh; Onyou Hwang
Journal:  J Biol Chem       Date:  2010-04-05       Impact factor: 5.157

5.  Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions.

Authors:  A Maeda; R A Sobel
Journal:  J Neuropathol Exp Neurol       Date:  1996-03       Impact factor: 3.685

6.  Reduction of apoptosis in ischemic retinas of two mouse models using hyperbaric oxygen treatment.

Authors:  Vera Gaydar; David Ezrachi; Olga Dratviman-Storobinsky; Shir Hofstetter; Bat Chen R Avraham-Lubin; Nitza Goldenberg-Cohen
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-29       Impact factor: 4.799

7.  Matrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors.

Authors:  Luis A Alcaraz; Lucia Banci; Ivano Bertini; Francesca Cantini; Antonio Donaire; Leonardo Gonnelli
Journal:  J Biol Inorg Chem       Date:  2007-08-21       Impact factor: 3.358

8.  MMP-2, -3 and -9 levels and activity are not related to Abeta load in the frontal cortex in Alzheimer's disease.

Authors:  S Baig; P G Kehoe; S Love
Journal:  Neuropathol Appl Neurobiol       Date:  2007-10-29       Impact factor: 8.090

Review 9.  The nerve growth factor signaling and its potential as therapeutic target for glaucoma.

Authors:  Haitao Wang; Rikang Wang; Thilini Thrimawithana; Peter J Little; Jiangping Xu; Zhong-Ping Feng; Wenhua Zheng
Journal:  Biomed Res Int       Date:  2014-08-31       Impact factor: 3.411

10.  Matrix metalloproteinase-3 causes dopaminergic neuronal death through Nox1-regenerated oxidative stress.

Authors:  Dong-Hee Choi; Ji-Hye Kim; Joo-Ha Seo; Jongmin Lee; Wahn Soo Choi; Yoon-Seong Kim
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

View more
  3 in total

1.  Tissue Inhibitor of Metalloprotease-2 (TIMP-2): Bioprocess Development, Physicochemical, Biochemical, and Biological Characterization of Highly Expressed Recombinant Protein.

Authors:  Anandã Chowdhury; Robert Brinson; Beiyang Wei; William G Stetler-Stevenson
Journal:  Biochemistry       Date:  2017-11-28       Impact factor: 3.162

2.  Knock-Out of Tenascin-C Ameliorates Ischemia-Induced Rod-Photoreceptor Degeneration and Retinal Dysfunction.

Authors:  Susanne Wiemann; Aisha Yousf; Stephanie C Joachim; Carolin Peters; Ana M Mueller-Buehl; Natalie Wagner; Jacqueline Reinhard
Journal:  Front Neurosci       Date:  2021-05-20       Impact factor: 4.677

3.  Ocular TGF-β, Matrix Metalloproteinases, and TIMP-1 Increase with the Development and Progression of Diabetic Retinopathy in Type 2 Diabetes Mellitus.

Authors:  Lucia Saucedo; Isabel B Pfister; Souska Zandi; Christin Gerhardt; Justus G Garweg
Journal:  Mediators Inflamm       Date:  2021-06-25       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.